imatinib (YD312)

News alerts, weekly reports and conference planners

Company:

YD Global

Drug class:

c-KIT inhibitor, SCF signal transduction pathway inhibitor

Related drugs:

No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2
No biomarker	Kaposi Sarcoma	No biomarker	Kaposi Sarcoma	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2
SDHB deletion	Gastrointestinal Stromal Tumor	SDHB deletion	Gastrointestinal Stromal Tumor	binimetinib + YD312 Sensitive: A2 - Guideline binimetinib + YD312 Sensitive : A2	binimetinib + YD312 Sensitive: A2 - Guideline binimetinib + YD312 Sensitive : A2
G0S2 overexpression	Chronic Myeloid Leukemia	G0S2 overexpression	Chronic Myeloid Leukemia	YD312 Sensitive: C3 – Early Trials YD312 Sensitive : C3	YD312 Sensitive: C3 – Early Trials YD312 Sensitive : C3
DNMT3A mutation	Chronic Myeloid Leukemia	DNMT3A mutation	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
ASXL1 mutation	Chronic Myeloid Leukemia	ASXL1 mutation	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
KMT2D underexpression	Chronic Myeloid Leukemia	KMT2D underexpression	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
XPC K939G	Chronic Myeloid Leukemia	XPC K939G	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
XPC K939G + XPC A499V	Chronic Myeloid Leukemia	XPC K939G + XPC A499V	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
SLC22A1 1222AG	Chronic Myeloid Leukemia	SLC22A1 1222AG	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
SLCO1B3 334TT	Chronic Myeloid Leukemia	SLCO1B3 334TT	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
SLCO1B3 334TG	Chronic Myeloid Leukemia	SLCO1B3 334TG	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
SLCO1B3 334T	Chronic Myeloid Leukemia	SLCO1B3 334T	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
SLC22A1 480CC + SLC22A1 1222AG + SLCO1B3 334TT + SLCO1B3 334TG	Chronic Myeloid Leukemia	SLC22A1 480CC + SLC22A1 1222AG + SLCO1B3 334TT + SLCO1B3 334TG	Chronic Myeloid Leukemia	YD312 Sensitive: C3 – Early Trials YD312 Sensitive : C3	YD312 Sensitive: C3 – Early Trials YD312 Sensitive : C3
FIP1L1-PDGFRA fusion	Chronic Eosinophilic Leukemia	FIP1L1-PDGFRA fusion	Chronic Eosinophilic Leukemia	YD312 Sensitive: C4 – Case Studies YD312 Sensitive : C4	YD312 Sensitive: C4 – Case Studies YD312 Sensitive : C4
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	dasatinib + nilotinib + YD312 + S81694 Sensitive: D – Preclinical dasatinib + nilotinib + YD312 + S81694 Sensitive : D	dasatinib + nilotinib + YD312 + S81694 Sensitive: D – Preclinical dasatinib + nilotinib + YD312 + S81694 Sensitive : D
KIT D816V	Acute Myelogenous Leukemia	KIT D816V	Acute Myelogenous Leukemia	YD312 Resistant: D – Preclinical YD312 Resistant : D	YD312 Resistant: D – Preclinical YD312 Resistant : D
KIT exon 8 mutation	Acute Myelogenous Leukemia	KIT exon 8 mutation	Acute Myelogenous Leukemia	YD312 Sensitive: D – Preclinical YD312 Sensitive : D	YD312 Sensitive: D – Preclinical YD312 Sensitive : D
ETV6-PDGFRB fusion	Acute Lymphocytic Leukemia	ETV6-PDGFRB fusion	Acute Lymphocytic Leukemia	YD312 Sensitive: D – Preclinical YD312 Sensitive : D	YD312 Sensitive: D – Preclinical YD312 Sensitive : D
NUP214-ABL1 fusion	Acute Lymphocytic Leukemia	NUP214-ABL1 fusion	Acute Lymphocytic Leukemia	YD312 Sensitive: D – Preclinical YD312 Sensitive : D	YD312 Sensitive: D – Preclinical YD312 Sensitive : D

imatinib (YD312)

Associations
(21)

Associations
(21)

imatinib (YD312)

Associations(21)

Associations(21)

Associations
(21)

Associations
(21)